The Evolution of HEOR in Rare Diseases: From Cost-Effectiveness to Strategic Market Access
There used to be a simple rule in pharma: scientists built the drug, clinical teams proved it worked, and health economists showed up near the end to do the math. Run the trial, demonstrate efficacy, ...
A Budget Impact Analysis Payers Can Trust: The Thelansis Framework
How the Thelansis budget impact modeling framework turns a payer's first and most literal question, "What will this cost my budget next year?" into a forecast a client can act on and a payer can indep ...
HER2-Positive Metastatic Breast Cancer: The Treatment Shift Reshaping the Market
A Decade of Reinvention There was a time when a HER2-positive breast cancer diagnosis carried a particularly difficult outlook. The biology was aggressive, treatment options were limited, and metasta ...
Beyond Market Size: How Patient, Epidemiology & Competitive Intelligence Can Shape Oncology Investment Strategies
Background: A biopharmaceutical company was evaluating the investment potential of a targeted oncology asset. Initial market assessments appeared attractive. The indication had a sizable patient popu ...
Evidence Without Context: Why Advanced Analytics Still Miss Commercial Reality
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet desp ...
Defining a Differentiated Target Product Profile (TPP) to Win in a Crowded Therapy Area
Background: The client was advancing a Phase II biologic in a chronic inflammatory disease category already dense with competition. While early clinical data showed encouraging efficacy and a managea ...